TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10650360
Drug: Periostat (subantimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periostat (subantimicrobial dose of doxycycline) in conjunction with scaling and root planing (SRP)
Study: 2240675
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 micrograms.ml‐1 (group C‐5)
Study: 2240675
Drug: Clonidine 10
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 10 micrograms.ml‐1 (group C‐10)
Study: 2240675
Drug: Epinephrine 5
Normalized name: epinephrine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 5 micrograms.ml‐1 (group E)
Study: 25514064
Drug: Dexmecamylamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmecamylamine (1 to 4 mg adjunct to SSRI/SNRI)
Study: 23435622
Drug: Enzastaurin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (500 mg/day) with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Study: 23435622
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Study: 22231005
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets (Corega Tabs)
Study: 22231005
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of effervescent tablets and ultrasonic device
Study: 17439507
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (12 g/day, p.o.)
Study: 17439507
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g/day of maltodextrin, p.o.)
Study: 16749287
Drug: Early mechanical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early mechanical revascularization with platelet glycoprotein IIb/IIIa inhibitors and drug-eluting stents, associated with strict glycemic control during hospital stay
Study: 10548198
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 20 ppm for 20 minutes
Study: 1959392
Drug: NCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP treatment correcting apneas, sleep fragmentation, and hypoxemia
Study: 1959392
Drug: NCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP treatment correcting apneas and sleep fragmentation while inducing intermittent hypoxemia
Study: 1959392
Drug: NCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP treatment under hypoxemic conditions
Study: 24239030
Drug: Interim methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim methadone (IM; methadone without counseling) for the first 4 months of 12 months of methadone treatment
Study: 22857721
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate (1 mg/kg body weight)
Study: 17003815
Drug: Vasopressin (non-pressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (non-pressor dose)
Study: 11849459
Drug: Glycine betaine
Normalized name: Glycine betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine betaine (GB) 4-g daily
Study: 11783251
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy (Group A)
Study: 8033606
Drug: Chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Group B)
Study: 11783251
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SQFZI) (Group C)
Study: 2194894
Drug: 500-mL gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mL gastric bubble (Ballobes) as an adjunct to diet, physical training, and behavioral modification
Study: 12468954
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide (40 mg, three times daily)
Study: 2583897
Drug: Oral L-Phe
Normalized name: L-Formula Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-Phe (100 mg/kg) + UVA exposure
Study: 2583897
Drug: Oral L-Phe
Normalized name: L-Formula Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-Phe (100 mg/kg) + UVA exposure + topical 10% L-Phe cream
Study: 25459096
Drug: Oxygen +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen + oral analgesics
Study: 24101747
Drug: Mindfulness-based course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based course (MBC) with eight weekly sessions of mindfulness education
Study: 17882008
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch releasing 14 microg of E2 per day
Study: 15756271
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg m(‐2) irinotecan (Group A)
Study: 15756271
Drug: 250, 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250, 350 or 500 mg m(‐2) irinotecan based on individual patient tolerance (Group B)
Study: 15756271
Drug: Individual dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dose escalation based on risk factor optimisation (Group C)
Study: 12359676
Drug: Paroxetine (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (to 60 mg/day)
Study: 12359676
Drug: Desipramine (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (to 30 mg/day)
Study: 7841427
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg
Study: 7841427
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg
Study: 2158257
Drug: Rifabutin 450
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 450 mg
Study: 30684325
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and pioglitazone
Study: 29786570
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and sulfonylureas
Study: 18723286
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.1mg/kg)
Study: 18723286
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.025mg/kg)
Study: 18723286
Drug: Naloxone (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (after morphine administration)
Study: 15494904
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (flucloxacillin or vancomycin)
Study: 8327367
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin administered 1 hr prior to the procedure
Study: 8327367
Drug: Flavored syrup
Normalized name: Oral Syrup (Flavored Syrup Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored syrup as placebo
Study: 2423813
Drug: Partially purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially purified bean-derived amylase inhibitor with 50 g of starch
Study: 30357819
Drug: Revascularization together
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revascularization together with Best Medical Therapy (BMT)
Study: 30357819
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Therapy (BMT) alone
Study: 21083671
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg
Study: 18329221
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg/day, n = 14)
Study: 18329221
Drug: Mirtazapine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (60 mg/day, n = 13)
Study: 18329221
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (pericyazine, 2.5‐10 mg/day, n = 22)
Study: 12909071
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone plus oral verapamil (group A+V)
Study: 12909071
Drug: Oral flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flecainide plus oral verapamil (group F+V)
Study: 12909071
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (group A)
Study: 12909071
Drug: Oral flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flecainide (group F)
Study: 11286371
Drug: Medical Resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Resonance Therapy Music (MRT-Music), 3 x 30 minutes per day for 14 days
Study: 8803961
Drug: Lacidipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (2 mg b.i.d. for 8 weeks)
Study: 1395455
Drug: OB +
Normalized name: RE OB + DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB + DZ (20 mg + 2 mg) T.I.D.
Study: 1395455
Drug: OB alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB alone (20 mg)
Study: 30344180
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin solution (HAS) administered to target serum albumin level of ≥35 g/L for up to 14 days or until discharge.
Study: 27633687
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin) prophylaxis
Study: 11146780
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiotherapy (45 Gy concurrent radiotherapy and fluorouracil 225‐250 mg/m(2) per day for 5 weeks)
Study: 25543183
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation (PA) therapy
Study: 21961489
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of metformin hydrochloride (1,000 mg)
Study: 21961489
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of metformin hydrochloride (1,000 mg)
Study: 16143129
Drug: ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid, 8‐10 mg/kg body weight daily (n = 42)
Study: 16143129
Drug: cholestyramine, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholestyramine, 8 g daily (n = 42)
Study: 12392588
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine (C-replete)
Study: 8076228
Drug: ondansetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (5 mg.m‐2)
Study: 8076228
Drug: metoclopramide (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (0.12 mg.kg‐1)
Study: 7944878
Drug: placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (saline solution)
Study: 2574554
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg once daily (qd)
Study: 2574554
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg twice daily (bid)
Study: 20626269
Drug: Raloxifene with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene with antiplatelet agents
Study: 20626269
Drug: Raloxifene without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene without antiplatelet agents
Study: 10607813
Drug: High-dose rhuMAb‐E25
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhuMAb‐E25 (5.8 microg/kg/nanogram IgE/mL)
Study: 10607813
Drug: Low-dose rhuMAb‐E25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rhuMAb‐E25 (2.5 microg/kg/nanogram IgE/mL)
Study: 20145608
Drug: Probiotic (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (2 capsules per day)
Study: 20145608
Drug: Probiotic (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (1 capsule + 1 placebo capsule per day)
Study: 331057
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules per day)
Study: 9856652
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5-fluorouracil (5FU)
Study: 9856652
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5-fluorouracil with paclitaxel
Study: 2691808
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Quazepam (QZP) for 8 weeks
Study: 603221
Drug: Practolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (0.2 mg/kg body weight) with atropine (0.01 mg/kg body weight)
Study: 31809985
Drug: Omega-3 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (oral Omega-3 2 g twice daily)
Study: 31292183
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg thiamine (control)
Study: 31292183
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg thiamine
Study: 31292183
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg thiamine
Study: 31292183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg thiamine
Study: 28167007
Drug: Sinuclean Nebules
Normalized name: Sinucleanse
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sinuclean Nebules treatment administered by nasal douche (Rinowash) twice/day for 10 days
Study: 28167007
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline administered by nasal douche (Rinowash) twice/day for 10 days
Study: 16440357
Drug: Preemptive lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Preemptive lamivudine therapy (100 mg daily from the start of TACL)
Study: 16440357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lamivudine therapy)
Study: 9132982
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablets (2 x 100 mg once a day for 7 days)
Study: 9132982
Drug: AVC suppositories
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVC suppositories (1.05 g sulfanilamide, 14 mg aminacrine hydrochloride, 140 mg allantoin twice a day for 7 days)
Study: 9132982
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (2 g as a single oral dose)
Study: 3721054
Drug: RV11 (propionyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV11 (propionyl erythromycin mercaptosuccinate) 500 mg oral dose
Study: 29962591
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg i.v.
Study: 29962591
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg and Dexamethasone 4 mg i.v.
Study: 24989060
Drug: Duloxetine 20-120
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20-120 mg/day
Study: 22393128
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and prednisone (10 mg/d)
Study: 20141566
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin
Study: 20141566
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of simvastatin
Study: 16127109
Drug: Hospital in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital in the Home (HITH) treatment
Study: 12789224
Drug: Cetirizine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 0.25 mg/kg orally twice daily for 1 week
Study: 10229311
Drug: Subcutaneous insulin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin: 0.1 IU/kg body weight/day of neutral protamine hagedorn (NPH) insulin once a day
Study: 6574528
Drug: Dexamethasone administered
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered at 1900h
Study: 6574528
Drug: Dexamethasone administered
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered at 2300h
Study: 26654211
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for recurrent MDD, 12-14 weeks duration
Study: 26654211
Drug: Continuation-phase CT
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo for higher risk patients (n = 241, 83%)
Study: 26654211
Drug: Continuation-phase therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation-phase therapy
Study: 11579985
Drug: Distraction (listening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction (listening to an audiotape) during the first hour of exposure treatment
Study: 11579985
Drug: Exposure without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure without distraction during the first hour of exposure treatment
Study: 1725912
Drug: Verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 360 mg/day
Study: 1101614
Drug: etidocaine 1%
Normalized name: etidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: etidocaine 1% with adrenaline (5 mug/ml)
Study: 1101614
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% with adrenaline (5 mug/ml)
Study: 22587850
Drug: Tai chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai chi twice a week (TC2)
Study: 20617220
Drug: Roughened implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roughened implant surfaces
Study: 12606165
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Cu/l solution
Study: 12606165
Drug: <0.01 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: <0.01 mg Cu/l solution (control)
Study: 7755076
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline solution containing a multivitamin preparation
Study: 2159860
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg gamma-linolenic acid
Study: 2159860
Drug: Indistinguishable placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguishable placebo capsules
Study: 9954
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg and 100 mg)
Study: 6849754
Drug: Oxprenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (80 mg)
Study: 29198872
Drug: ACB single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB single injection with IV Dex 8 mg
Study: 29198872
Drug: ACB single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB single injection without IV Dex
Study: 22800401
Drug: Omalizumab treatment
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab treatment for 6 months
Study: 16095548
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESIs) with local anaesthetic
Study: 30241561
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline injection)
Study: 26815247
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESIs)
Study: 12189359
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (100 mg)
Study: 12189359
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (200 mg)
Study: 2945499
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loratadine
Study: 7547368
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy withdrawal
Study: 7547368
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with anticoagulant therapy
Study: 1953230
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of various conventional antirheumatic drugs
Study: 7284971
Drug: Moderate-dose (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU)
Study: 7284971
Drug: High-dose (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (6000 rads) radiation + 5-fluorouracil (5-FU)
Study: 7284971
Drug: High-dose (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (6000 rads) radiation alone
Study: 27085323
Drug: nab-Paclitaxel (nab-P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-Paclitaxel (nab-P) 125 mg/m² + Gemcitabine (Gem) 1000 mg/m²
Study: 27085323
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gem) 1000 mg/m²
Study: 25129475
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with target-controlled infusion (TIVA-TCI)
Study: 25129475
Drug: Balanced inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced inhalation anaesthesia (BAL)
Study: 15897583
Drug: Flaxseed muffin
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed muffin (25 g daily)